ACHL Achilles Therapeutics plc

6.19
+0.21  (+4%)
Previous Close 5.98
Open 5.98
52 Week Low 5.76
52 Week High 18.9476
Market Cap $251,448,639
Shares 40,621,751
Float 40,621,751
Enterprise Value $93,635,808
Volume 16,935
Av. Daily Volume 41,731
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ATL001 - THETIS
Melanoma
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ATL001 - CHIRON
Non Small Cell Lung Cancer
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. - Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator -

    - CHIRON trial is enrolling up to 40 patients with advanced unresectable or metastatic non-small cell lung cancer at clinical sites in the UK, EU and the US -        

    LONDON, July 01, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the first patient in the United States (US) has been enrolled in the Company's ongoing Phase I/IIa CHIRON clinical trial. CHIRON is an open-label, multi-center Phase I/IIa trial evaluating the safety, tolerability, and activity of clonal neoantigen T cell (cNeT…

    - Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator -

    - CHIRON trial is enrolling up to 40 patients with advanced unresectable or metastatic non-small cell lung cancer at clinical sites in the UK, EU and the US -        

    LONDON, July 01, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the first patient in the United States (US) has been enrolled in the Company's ongoing Phase I/IIa CHIRON clinical trial. CHIRON is an open-label, multi-center Phase I/IIa trial evaluating the safety, tolerability, and activity of clonal neoantigen T cell (cNeT) therapy as a single dose in adult patients with advanced metastatic non-small cell lung cancer (NSCLC). cNeT are selectively expanded T cells that target a patient's own clonal neoantigens which are present on all tumor cells but absent from healthy tissue.

    This first US patient was enrolled at the Moffitt Cancer Center in Tampa, FL where Dr. Benjamin Creelan is the Principal Investigator. CHIRON is now open at 10 sites in the UK, EU and the US.

    "We are delighted to have taken our cutting-edge, cNeT platform into the US with the successful enrollment of the first patient at the Moffitt Cancer Center in our ongoing CHIRON study," said Dr Iraj Ali, CEO of Achilles Therapeutics. "With our cNeT platform we prospectively target patient-specific clonal neoantigens and are able to generate comprehensive characterization including the dose of the active cNeT component for each product. We look forward to providing an update from 10 patients across our CHIRON and THETIS studies in NSCLC and melanoma, respectively, in the fourth quarter of this year where we will present data highlighting a basis for our proposed potency assay."

    CHIRON is expected to recruit approximately 40 patients with advanced unresectable or metastatic NSCLC. The primary objective of the trial is to assess the safety and tolerability of cNeT. Clinical efficacy will be evaluated as a secondary measure. Additional data evaluating cNeT persistence, phenotype, and functionality will be reviewed while also exploring potential biomarkers of clinical activity and factors affecting response. This will include analysis of patient samples using a bespoke plasma ctDNA assay.

    "There is still a large unmet need in NSCLC where there are very limited options for relapsed patients. We at the Moffitt are pleased to be the first US-based site for the CHIRON study to evaluate this important, precision tumor-infiltrating lymphocyte therapy," said Dr Benjamin C Creelan, Principal Investigator of the CHIRON study and thoracic oncologist at Moffitt Cancer Center. "This is the first US patient to be enrolled to receive a precision T cell therapy specifically targeting clonal neoantigens and we are pleased to be working with the team at Achilles."

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    Forward-Looking Statements

    This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Further information:

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000



    Primary Logo

    View Full Article Hide Full Article
  2. LONDON, United Kingdom, June 04, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, which is being held in a virtual format from June 4-8, 2021. The poster presentation given by Dr Mariam Jamal-Hanjani, scientific investigator for CHIRON and Medical Oncologist from the Cancer Research UK Lung Cancer Centre of Excellence, highlights the design of the ongoing phase I/IIa CHIRON clinical trial evaluating clonal neoantigen T cells (cNeT) in patients with advanced non-small cell lung cancer (NSCLC).

    The primary objective of the trial…

    LONDON, United Kingdom, June 04, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, which is being held in a virtual format from June 4-8, 2021. The poster presentation given by Dr Mariam Jamal-Hanjani, scientific investigator for CHIRON and Medical Oncologist from the Cancer Research UK Lung Cancer Centre of Excellence, highlights the design of the ongoing phase I/IIa CHIRON clinical trial evaluating clonal neoantigen T cells (cNeT) in patients with advanced non-small cell lung cancer (NSCLC).

    The primary objective of the trial is to assess the safety and tolerability of cNeT as monotherapy and in combination with pembrolizumab, an immune checkpoint inhibitor, and will also evaluate the clinical efficacy as a secondary measure. Additional data evaluating cNeT persistence, phenotype, and functionality will be reviewed while also exploring potential biomarkers of clinical activity and factors affecting response. This will include analysis of patient samples using a bespoke plasma ctDNA assay.

    "With 75% of patients with NSCLC presenting with inoperable or metastatic disease and a 5-year survival for stage IV disease as low as 5%, additional treatments are needed for this large patient population including autologous cell therapies like Achilles' cNeT," commented Dr Jamal-Hanjani. "The rationale of the CHIRON trial is very evident as we know that NSCLC patients with tumors that have a high burden of clonal neoantigens have improved disease free survival and increased sensitivity to checkpoint inhibition."

    "Just as with our THETIS melanoma trial, CHIRON allows us to look at the safety and tolerability of our precision cNeT as monotherapy and in combination with a checkpoint inhibitor," said Dr Karl Peggs, Chief Medical Officer of Achilles. "While the primary purpose of the trials is safety, the addition of these checkpoint combination cohorts will allow further examination of T cell kinetics and the contribution of cell dose and checkpoint therapy to treatment outcomes. Further, we will continue to look at the predictive value of ctDNA as a potential marker for clinical events as we look towards the future of our product with potential companion diagnostics in addition to our planned potency assays."

    All patients enrolled in CHIRON will have been treated with at least one prior systemic therapy, inclusive of a checkpoint inhibitor unless contraindicated, have Eastern Cooperative Oncology Group (ECOG) Status 0-1, have locally advanced or metastatic disease, and have accessible sites for collection of adequate tissue. Patients requiring regular immunosuppression (including steroids at a dose equivalent to prednisolone 10 mg/day or greater) or that have previously received any investigational cell or gene therapies are not eligible.

    Details of the abstract and poster presentation are as follows:

    Abstract TitleAn open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON)

    Poster Number: TPS9138

    Poster Session: Lung Cancer—Non-Small Cell Metastatic



    The poster accompanied by a recording from Dr Jamal-Hanjani and full session details are available at www.asco.org. The poster is also available in the Events & Presentations section of the Achilles website at https://ir.achillestx.com/events-and-presentations.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    Forward-Looking Statements

    This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Further information:

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

     

    Consilium Strategic Communications

    Mary-Jane Elliott, Matthew Cole, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000



    Primary Logo

    View Full Article Hide Full Article
  3. - Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -

    - Completed initial public offering of ADSs raising $175.5 million in gross proceeds -        

    LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights.

    "Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating…

    - Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -

    - Completed initial public offering of ADSs raising $175.5 million in gross proceeds -        

    LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights.

    "Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating our precision TIL cNeT therapy in patients with non-small cell lung cancer and melanoma, respectively, and priced our successful US initial public offering on Nasdaq, which closed just after quarter-end," said Dr Iraj Ali, Chief Executive Officer of Achilles. "We continue to enroll and dose patients and have opened our first clinical sites in the US and EU. This year, we expect to report interim data from a total of ten patients that have received cNeT monotherapy across the CHIRON and THETIS trials and will also begin enrolling patients to receive higher dose cNeT. In addition, we will open Cohort B in the THETIS study to evaluate the addition of a PD-1 inhibitor to our cNeT therapy."

    Business Highlights

    • Received a recommendation from the Independent Data Safety Monitoring Committee to continue the ongoing Phase I/IIa CHIRON and THETIS trials as planned
    • Announced initial clinical data from the first six patients dosed with the Company's cNeT therapy showing encouraging evidence of cNeT engraftment, an overall tolerability profile similar to that of standard TIL products, stable disease in four out of the six patients, and one patient with tumor lesion reduction
    • Presented data at the American Association of Cancer Research (AACR) annual meeting detailing the Company's comprehensive translational research program and insights into the in vivo dynamics of cNeT post-dosing, and the potential to develop a potency-based release assay
    • Strengthened the Board of Directors and Scientific Advisory Board with the additions of Julie O'Neill and Markwin Velders, Ph.D., respectively, and continued to build the team in the UK & US, including key appointments across manufacturing, supply chain and clinical operations, bio-processing and intellectual property
    • Received a Horizon 2020 grant as part of the Neoantigen Consortium, with the aim of developing a tool to predict neoantigen immunogenicity.

    Financial Highlights

    • IPO: Priced an initial public offering of 9,750,000 ADRs at a public offering price of $18.00 per share for gross proceeds of $175.5 million. The IPO closed on April 6, 2021, after the quarter end.
    • Cash and cash equivalents: Cash and cash equivalents were $159.3 million as of March 31, 2021 as compared to $177.8 million as of December 31, 2020, not including $160.6 million in net proceeds from the IPO which closed on April 6, 2021. The Company anticipates that its existing cash and cash equivalents plus the IPO proceeds are sufficient to fund its planned operations into the second half of 2023, including full funding of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.
    • Operating Expenses: Operating Expenses were $13.7 million for the quarter ended March 31, 2021, which included $8.9 million in Research & Development, and General and Administrative expenses of $4.8 million.
    • Net loss: Net loss attributable to ordinary shareholders was $13.8 million for the quarter ended March 31, 2021 and the basic and diluted net loss per ordinary share was $8.38 for the quarter ended March 31, 2021.

    Upcoming Events

    • Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference at on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.
    • A poster detailing abstract TPS9138 entitled, An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Clonal Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON), will be presented at the 2021 ASCO Annual Meeting taking place virtually from June 4-9, 2021. Full abstracts will be released on May 19, 2021 at ASCO.org.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    Forward-Looking Statements

    This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Further information:

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000

    ACHILLES THERAPEUTICS PLC

    Condensed Consolidated Balance Sheets (Unaudited)

    (in thousands, except share and per share amounts)

    (expressed in U.S. Dollars, unless otherwise stated)

      March 31,  December 31, 
      2021  2020 
    ASSETS        
    Current assets:        
    Cash and cash equivalents $159,262  $177,849 
    Prepaid expenses and other current assets  14,058   9,948 
    Total current assets  173,320   187,797 
    Non-current assets:        
    Property and equipment, net  15,479   13,369 
    Operating lease right of use assets  14,155   14,740 
    Deferred tax assets  4   4 
    Other assets  3,145   3,008 
    Total non-current assets  32,783   31,121 
    TOTAL ASSETS $206,103  $218,918 
    LIABILITIES AND SHAREHOLDERS' EQUITY        
    Current liabilities:        
    Accounts payable $1,787  $6,314 
    Income taxes payable  19   7 
    Accrued expenses and other liabilities  8,646   6,590 
    Operating lease liabilities-current  4,610   3,712 
    Total current liabilities  15,062   16,623 
    Non-current liabilities:        
    Operating lease liabilities-non-current  11,329   12,271 
    Other long-term liability  659   652 
    Total non-current liabilities  11,988   12,923 
    Total liabilities  27,050   29,546 
    Commitments and contingencies (Note 11)        
    Shareholders' equity:        
    Ordinary shares, £0.001 par value; 30,853,489 and 4,389,920 shares

    authorized, issued and outstanding at March 31, 2021 and December

    31, 2020, respectively
      6   6 
    Deferred shares, £0.001 par value; 109,058 and 30,521 shares issued and

    outstanding as of March 31, 2021 and December 31, 2020, respectively
          
    Convertible preferred shares, £0.001 par value; no shares authorized,

    issued and outstanding as of March 31, 2021;104,854,673 shares

    authorized, issued and outstanding at December 31, 2020
      134   134 
    Additional paid in capital  236,305   234,922 
    Accumulated other comprehensive income  14,385   12,322 
    Accumulated deficit  (71,777)  (58,012)
    Total shareholders' equity  179,053   189,372 
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $206,103  $218,918 
             

    ACHILLES THERAPEUTICS PLC

    Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

    (in thousands, except share and per share amounts)

      Three Months Ended March 31, 
      2021  2020 
    OPERATING EXPENSES:        
    Research and development $8,876  $3,830 
    General and administrative  4,832   1,736 
    Total operating expenses  13,708   5,566 
    Loss from operations  (13,708)  (5,566)
    OTHER INCOME (EXPENSE), NET:        
    Other income (expense)  (45)  352 
    Total other income (expense), net  (45)  352 
    Loss before provision for income taxes  (13,753)  (5,214)
    Provision for income taxes  (12)   
    Net loss  (13,765)  (5,214)
    Other comprehensive income:        
    Foreign exchange translation adjustment  2,063   (6,510)
    Comprehensive loss $(11,702) $(11,724)
    Net loss per share attributable to ordinary shareholders—basic and diluted $(8.38) $(6.13)
    Weighted average ordinary shares outstanding—basic and diluted  1,641,938   850,377 
             



    Primary Logo

    View Full Article Hide Full Article
  4. LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumor neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.

    "Immunotherapy has revolutionized cancer treatment, providing survival benefits to patients with hard-to-treat tumors…

    LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumor neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.

    "Immunotherapy has revolutionized cancer treatment, providing survival benefits to patients with hard-to-treat tumors. There is an increasing call for personalized, precision therapies to induce immune responses against tumor-specific targets," said Dr Sergio Quezada, Chief Scientific Officer of Achilles. "This grant is a further validation of the work being done at Achilles by our team of world-class scientists. The contribution of our deep experience with neoantigen prediction algorithms and our innovative platform technology will allow the consortium to work toward identifying new immunotherapeutic targets and effective anticancer therapies."

    Current technologies struggle to discriminate immunogenic tumor neoantigens from the thousands of background mutations in tumors at scale. The consortium will work together to develop a high throughput neoantigen immunogenicity profiling platform. The project, named DECOD-Ag, will be conducted by a team of world-leading, interdisciplinary scientists from the consortium with expertise in cancer immunotherapy, bioinformatics, peptidomics, mass spectrometry, immune monitoring, clinical and translational medicine.

    This project has received €3 million ($3.6 million) from the European Union's Horizon 2020 research and innovation programme under the FETOPEN grant agreement number 964998. Approximately €0.8 million ($1 million) will be allocated to Achilles.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    About the Consortium Members

    UCL

    UCL is London's leading multidisciplinary university, with more than 13,000 staff and 42,000 students from 150 different countries. Through a progressive approach to teaching and research, our world leading academics, curious students and outstanding staff continually pursue excellence, break boundaries, and make an impact on real world problems. UCL is consistently ranked as one of the top performing organisations worldwide under the EU Framework Programmes for research.

    The Francis Crick Institute

    The Francis Crick Institute is a biomedical research institute located in London, UK. The Institute's ambition is to discover the fundamental biology underlying human health and diseases. The Institute's work helps to understand why disease develops and to find new ways to diagnose, prevent and treat a range of illnesses − such as cancer, heart disease, stroke, infections and neurodegenerative diseases. The Institute brings together outstanding scientists from all disciplines, carrying out research that will help improve the health and quality of people's lives, and keep the UK at the forefront of medical innovation.

    The Weizmann Institute of Science

    The Weizmann Institute of Science in Israel is one of the world's top-ranking multidisciplinary research institutions and offers masters' and doctoral-level degrees across five faculties, noted for its wide-ranging exploration of the natural and exact sciences. Institute scientists are advancing research on the human brain, artificial intelligence, computer science and encryption, astrophysics and particle physics, and they are tackling diseases such as cancer, and addressing climate change through environmental, ocean and plant sciences, and more.

    Technical University of Denmark

    DTU was founded in 1829 with the mission of creating value for the benefit of society. DTU is an international elite technical university where education, scientific advice, and innovation rest on a solid foundation of world-class research. The University is at the academic and multidisciplinary forefront of the technical and the natural sciences - with new initiatives in a number of demanding engineering disciplines such as life science.

    About Horizon 2020

    Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe's global competitiveness.

    By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

    For further information please visit: https://ec.europa.eu/programmes/horizon2020/.

    Forward-Looking Statements

    This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000



    Primary Logo

    View Full Article Hide Full Article
  5. LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.

    A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface…

    LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.

    A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    Further information:

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000

     



    Primary Logo

    View Full Article Hide Full Article
View All Achilles Therapeutics plc News